Journals / Journal of Mood Disorders / 2015 / Cilt: 5 - Sayı: 2

Tedaviye dirençli depresyonda ketamin infüzyonu: Bir vaka sunumu ve literatürün kısa gözden geçirilmesi

Ketamine Infusion in Treatment Resistant Depression: A Case Report and Brief Review of The Literature

Pages
78–82
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although additional research is neededto ascertain optimal dosing schedules and route ofadministration of ketamine, NMDA agents warrant furtherinvestigation as a treatment option in treatment-resistantdepression and as an agent intended to reduce suicides.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The glutamate N-methyl-D-aspartate (NMDA) receptorantagonist ketamine may exhibit antidepressant effect.Previous studies of treatment-resistant depression revealthat ketamine infusions may result in a rapid antidepressantresponse with improvement usually sustained for severaldays.
📊
Key Findings & Data:This case suggests that intravenous administrationof ketamine may be effective for immediate relief fromsymptoms in unipolar depression and may also relievesuicidal ideation.
💡
Conclusion & Impact:Although additional research is neededto ascertain optimal dosing schedules and route ofadministration of ketamine, NMDA agents warrant furtherinvestigation as a treatment option in treatment-resistantdepression and as an agent intended to reduce suicides.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The glutamate N-methyl-D-aspartate (NMDA) receptorantagonist ketamine may exhibit antidepressant effect.Previous studies of treatment-resistant depression revealthat ketamine infusions may result in a rapid antidepressantresponse with improvement usually sustained for severaldays. This case suggests that intravenous administrationof ketamine may be effective for immediate relief fromsymptoms in unipolar depression and may also relievesuicidal ideation. Due to the prolonged period between theinitiation of treatment and the onset of action of currentlyavailable antidepressants, only a few things can be donefor the management of acute and severe suicidal ideationother than close monitoring or hospitalization. Rapid effectof ketamine may be an advantage in the managementof suicide risk. Although additional research is neededto ascertain optimal dosing schedules and route ofadministration of ketamine, NMDA agents warrant furtherinvestigation as a treatment option in treatment-resistantdepression and as an agent intended to reduce suicides.

Özet

Glutamat N-metil-D-aspartat reseptör antagonisti olanketamin antidepresan etkinlik gösterebilmektedir.Tedaviye dirençli depresyon olgularında yürütülmüş olanaraştırmalarda ketamin infüzyonu hızlı başlangıçlı ve birkaçgün süren bir antidepresan etkinlik göstermiştir. Bu olgusunumunda intravenöz ketamin uygulaması sonrası tekuçlu depresif dönemde belirtilerde ve intihar düşüncesindehızlı yatışma izlenmiştir. Mevcut antidepresanların etkibaşlangıcı için uzun süre gerektirmesi nedeniyle akut veşiddetli intihar düşüncesinin klinik tedavisinde yakın izlemveya hastaneye yatırma dışında çok az seçenek vardır.Ketaminin hızlı etkinliği intihar riski yüksek hastaların elealınmasında bir avantaj sağlayabilir. Ketaminin optimaldoz ve uygulama yollarının belirlenmesi için çalışmalargerekli olmakla birlikte, NMDA üzerine etkili ajanlar dirençli depresyon tedavisi ve intihar riskinin azaltılması için birseçenek olarak daha fazla araştırmayı hak etmektedir.

🔖

Cite This Article

HIZLI, G. S., SAVAŞ, A. H., ÖZTEN, E. (2022). Tedaviye dirençli depresyonda ketamin infüzyonu: Bir vaka sunumu ve literatürün kısa gözden geçirilmesi. Journal of Mood Disorders, Cilt: 5 - Sayı: 2, 78–82. https://ajindex.com/articles/649269

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ebrinç S. Innovations in treatment of treatment-resistant unipolar depression. Journal of Mood Disorders. 2013;3(Suppl 1):S51-S3
  2. Karolewicz B, Çetin M, Arıcıoğlu F. Majör depresif bozuklukta glutamat N-metil-D-aspartat reseptörlerinin ötesi: mTOR sinyal yolağı. Bulletin of Clinical Psychopharmacology. 2011;21:1-6
  3. Brittner M, Micoulaud-Franchi JA, Richieri R, Boyer L, Adida M, Lancon C, et al. Ketamine in acute and severe major depressive disorder. Presse Medicale. 2014;43:492-500
  4. Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Medicine. 2006;7:92-5
  5. Covvey JR, Crawford AN, Lowe DK. Intravenous ketamine for treatment-resistant major depressive disorder. The Annals of Pharmacotherapy. 2012;46:117-23
  6. Eken B, Verimli A, İzbırak G, Er FO. Use of lamotrigine in psychiatric disorders. Anadolu Psikiyatri Dergisi. 2008;9:169-78
  7. Zarate CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al. An open-label trial of riluzole in patients with treatment- resistant major depression. The American Journal of Psychiatry. 2004;161:171-4
  8. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine. 2015;45:693-704
  9. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. 2000;47:351-4
  10. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment- resistant major depression: a two-site randomized controlled trial. The American Journal of Psychiatry. 2013;170:1134-42
  11. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders. 2015;17:438-43
  12. Fond G, Loundou A, Rabu C, Macgregor A, Lancon C, Brittner M, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231:3663- 76
  13. Ghasemi M, Kazemi MH, Yoosefia A, Ghasemic A, Paragomi P, Amini H, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Re